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IMPORTANCE Since publication of the report by the Panel on Cost-Effectiveness in Health and
Medicine in 1996, researchers have advanced themethods of cost-effectiveness analysis,
and policy makers have experimented with its application. The need to deliver health care
efficiently and the importance of using analytic techniques to understand the clinical and
economic consequences of strategies to improve health have increased in recent years.
OBJECTIVE To review the state of the field and provide recommendations to improve the
quality of cost-effectiveness analyses. The intended audiences include researchers,
government policy makers, public health officials, health care administrators, payers,
businesses, clinicians, patients, and consumers.
DESIGN In 2012, the Second Panel on Cost-Effectiveness in Health andMedicine was formed
and included 2 co-chairs, 13 members, and 3 additional members of a leadership group. These
members were selected on the basis of their experience in the field to provide broad
expertise in the design, conduct, and use of cost-effectiveness analyses. Over the next 3.5
years, the panel developed recommendations by consensus. These recommendations were
then reviewed by invited external reviewers and through a public posting process.
FINDINGS The concept of a “reference case” and a set of standardmethodological practices
that all cost-effectiveness analyses should follow to improve quality and comparability
are recommended. All cost-effectiveness analyses should report 2 reference case analyses:
one based on a health care sector perspective and another based on a societal perspective.
The use of an “impact inventory,” which is a structured table that contains consequences
(both inside and outside the formal health care sector), intended to clarify the scope and
boundaries of the 2 reference case analyses is also recommended. This special
communication reviews these recommendations and others concerning the estimation of the
consequences of interventions, the valuation of health outcomes, and the reporting of
cost-effectiveness analyses.
CONCLUSIONS AND RELEVANCE The Second Panel reviewed the current status of the field of
cost-effectiveness analysis and developed a new set of recommendations. Major changes
include the recommendation to perform analyses from 2 reference case perspectives and to
provide an impact inventory to clarify included consequences.
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I
n 1993, the US Public Health Service convened a panel of 13
nongovernment scientists and scholars with expertise in eco-
nomics, clinical medicine, ethics, and statistics to review the
state of cost-effectiveness analysis and to develop recommenda-
tions for its conduct and use in health and medicine (a glossary of
terms appears in the Box).1 The primary goals were to improve the
quality of cost-effectiveness analyses and promote comparability
across studies.
In 1996, the original Panel on Cost-Effectiveness in Health and
Medicinepublished its findings in a seriesof articles in JAMA,2-4and
in a book.1 The panel emphasized that the growing field of cost-
effectiveness analysis providedanopportunity to rationalizehealth
policy if the techniqueand its applicationwerewell understoodand
implemented.
During the 20 years since the release of the panel’s report, the
number of published cost-effectiveness analyses has increased
substantially. Moreover, the field has advanced in many ways such
as by strengthening its theoretical foundations; improving meth-
ods for evidence synthesis, modeling, and uncertainty analysis;
considering more closely the ethical issues surrounding the use of
cost-effectiveness analysis; and standardizing requirements for
the reporting of results. During the same period, health care also
has experienced substantial changes in terms of its use of techno-
logical advances and the organization, financing, cost, and delivery
of care. New uses of cost-effectiveness analysis have also emerged
in the United States and abroad. Examples from the United States
include the use of cost-effectiveness analysis by the Advisory
Committee for Immunization Practices, which establishes national
immunization policy recommendations on behalf of the US Cen-
ters for Disease Control and Prevention.5 A prominent example in
the United Kingdom is the use of cost-effectiveness analysis by
the National Institute of Health and Care Excellence, which is a
nondepartmental public body created in 1999 that serves England
andWales.6
The need to deliver health care efficiently and the importance
of using analytic techniques to understand the clinical and eco-
nomic consequences of strategies to improve health have only
increased. Health care spending in the United States comprised
13% of gross domestic product in 1995; in 2014, it approached
18%.7 For these reasons, an update of the original panel’s efforts
is important.
Methods
In 2011, members of the original panel began planning for an
update to the 1996 recommendations. Over the next year, a leader-
ship group was formed that included the eventual co-chairs (G.D.S.
and P.J.N.) of the Second Panel on Cost-Effectiveness in Health and
Medicine and coauthors of this article (L.B.R., J.E.S., and T.G.G.).
This leadership group convened a new panel during the fall 2012
and developed a process for updating the original report.
The 13 individuals invited to join the Second Panel were in-
vited by the leadership group (after consultation with members
of the first panel and other advisors) and selected on the basis of
their experience in the field to provide broad expertise in the
design, conduct, and use of cost-effectiveness analyses. Three
international members (D.F., M.K, and M.J.S.) reflected the per-
spectives and experiences of other countries that have used cost-
effectiveness analysis. The group met as a full panel through regu-
lar teleconferences beginning in early 2013 and held 5 in-person
meetings over the next few years to update the recommendations.
The Second Panel has updated and expanded the recommen-
dations of the original panel in numerous ways. The panel consid-
ered each of the original recommendations and the need tomodify
Box. Glossarya
Cost-benefit analysis: An analytic tool for estimating the net social
benefit of a program or intervention as the incremental benefit
of the programminus the incremental cost, with all benefits and
costs measured in US dollars.
Cost-effectiveness analysis: An analytic tool in which the costs
and effects of a program and at least 1 alternative are calculated
and presented in a ratio of incremental cost to incremental effect.
Effects are health outcomes, such as cases of a disease prevented,
years of life gained, or quality-adjusted life-years, rather than
monetary measures as in cost-benefit analysis.
Disaggregatedmeasures: Attribution of total costs or
quality-adjusted life-years to intermediate categories associated
with specific cost categories (eg, intervention-specific vs relating
to the care of the condition, health care sector vs other sector)
or intermediate health outcomes. A typical breakdown of costs
into disaggregatedmeasures would report intervention-specific
and condition-related costs, along with more detailed categories
as relevant (eg, hospitalization, outpatient visits). Other categories
may be relevant depending on the decision context.
Discounting: The process of converting future dollars and future
health outcomes to their present values.
Health care sector perspective: A viewpoint for conducting
a cost-effectiveness analysis that includes formal health care
sector (medical) costs borne by third-party payers and paid
out-of-pocket by patients. These third-party and out-of-pocket
medical costs include current and future costs, related and
unrelated to the condition under consideration.
Incremental cost-effectiveness ratio: The ratio of the difference
in costs between 2 alternatives to the difference in effectiveness
between the same 2 alternatives.
Net health benefit: Linear combination of costs and effects,
expressed in effectiveness units.
Netmonetary benefit: Linear combination of costs and effects,
expressed in US dollars.
Perspective: The viewpoint fromwhich a cost-effectiveness
analysis is conducted.
Quality-adjusted life-year: Ameasure of health outcome
that assigns a weight to each period (ranging from0 to 1),
corresponding to the health-related quality of life during that
period, in which a weight of 1 corresponds to optimal health,
and a weight of 0 corresponds to a health state judged equivalent
to death; these are then aggregated across periods.
Reference case: A set of standardmethodological practices
that all cost-effectiveness analyses should follow to improve
comparability and quality.
Societal perspective: A viewpoint for conducting
a cost-effectiveness analysis that incorporates all costs and
health effects regardless of who incurs the costs and who obtains
the effects.
aAdapted from glossary in Gold et al.1
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or expand them based on changes in the field. For new topic areas
(decision modeling, evidence synthesis, ethics), panel members
drafted recommendations de novo. Throughout the process, draft
recommendations were circulated first among chapter authors and
then more broadly among the panel as a whole for email, telecon-
ference, and in-person discussion and consensus. If consensus was
not possible, the plan was for the panel to vote, with an 80%
majority required to pass and with the option for a minority report.
Consensus was reached relatively easily on most recommenda-
tions. Two exceptions were recommendations about perspectives
for the reference case (whether to recommend 1, 2, or more per-
spectives and how to define them) and on productivity (whether to
include it in the numerator or denominator of the incremental cost-
effectiveness ratio). After further discussion, consensus was
reached on these and all other issues without the need for a formal
vote and without anyminority reports.
The Second Panel benefited from the active participation of
somemembersof theoriginal panel, and fromreviewof itsworkby
experts in the field through both an external review process and a
public commentperiod (participantsof this process are listed in the
additional contributions section at the end of the article).
The objectives were to review the state of the field and pro-
viderecommendations to improvethequalityandpromotethecom-
parabilityofcost-effectivenessanalyses.The intendedaudiencesare,
in addition to students and researchers, government policy mak-
ers, public health officials, health care administrators, payers, busi-
nesses, clinicians, patients, and consumers.
The landscape and the set of challenges to cost-effectiveness
analysis have changed since 1996. Cost-effectiveness analysis is
no longer a nascent approach, and variation in published studies
cannot be ascribed to the newness of its concepts or methods.
Compared with the original panel, the Second Panel had the
advantage of drawing on 2 decades of methodological and policy
advances. However, the Second Panel also had the challenge of
sifting through and trying to make sense of the diverse and some-
times contrasting opinions about and experiences with cost-
effectiveness analysis.
Key Recommendations
Overview
Cost-effectiveness analysis can help inform decisions about how to
applyneworexistingtests,therapies,andpreventiveandpublichealth
interventions so that they represent a judicious use of resources. It
also can help to fill gaps in the evidence about the estimated popu-
lation-level public health effect of such interventions, and can sup-
port decisions to disinvest in older interventions for which there are
more cost-effective alternatives. Cost-effectiveness analysis pro-
videsa framework for comparing the relativevalueofdifferent inter-
ventions, alongwith information that can help decisionmakers sort
throughalternativesanddecidewhichonesbestservetheirprogram-
matic and financial needs.
The full set of recommendations are included in the eAppen-
dix in theSupplement.Thecomplete reportwill bepublished inbook
forminOctober2016.8ThisSpecialCommunicationsummarizeskey
recommendations regarding the referencecaseandstudyperspec-
tives, as well as other important aspects of the report.
Reference Cases
The original panel recommended a reference case, which is a set of
standardmethodological practices that all cost-effectiveness analy-
ses should follow to improve comparability and quality.1 It further
recommended that reference case analyses take a societal per-
spective to reflect the perspective of a decision maker whose
intention is to make decisions about the broad allocation of
resources across the entire population. In a cost-effectiveness
analysis conducted from a societal perspective, the analyst consid-
ers all parties affected by the intervention and counts all significant
outcomes and costs that flow from it, regardless of who experi-
ences the outcomes or bears the costs. The original panel also
noted that, to address specific decision contexts, analysts might
also include narrower perspectives, such as that of the health care
sector, to reflect the view of a decision maker whose responsibility
rests only within that sector. The Second Panel endorses the refer-
ence case concept for the purposes originally intended, namely to
improve the quality of cost-effectiveness analyses and promote
comparability across studies.
Societal Perspective: Experience Since the Original Panel
Since publication of the original panel’s recommendations in 1996,
there has been a substantial increase in the number of published
cost-effectiveness analyses, andmany have not used a societal per-
spective as defined by the original panel.9-12 One study found, for
example, that only 341 (29%) of 1163 cost per quality-adjusted life-
year (QALY) analyses published through 2005 adopted a societal
perspective.11 Even when analysts have stated that they have used
a societal perspective, they have often omitted potentially impor-
tant elements, such as costs related to patient and caregiver time,
or to transportation or non–health care sectors (eg, education), so
that the perspective of the analysis is essentially a narrower
one.11,13-15 Moreover, since 1996, decision-making bodies primarily
in Europe, Australia, and Canada have formally incorporated cost-
effectiveness analysis into health technology assessment pro-
cesses to inform coverage and reimbursement decisions, but gen-
erally have not adopted a societal perspective, preferring instead a
more focused health system perspective. Others have highlighted
the theoretical challenges associated with aggregating the costs
and effects that fall on different sectors and individuals in a way
that reflects a consensus position on social welfare.16,17
Panel’s Reference Case Recommendations
The following recommendations are important to promote qual-
ity and comparability, while also recognizing (1) the different pref-
erences, types of interventions, needs, and authorities of decision
makers, (2) the importance of preserving flexibility for analysts
in accommodating those factors, and (3) the value that stems
from illustrating the consequences of decisions from different
viewpoints.
Recommendation 1: Reference Cases and Perspectives
All studies should report a reference case analysis based on a
health care sector perspective and another reference case analy-
sis based on a societal perspective. The reference cases are
defined by recommendations for components to consider for
evaluation, methods to use, and elements for reporting. It is rec-
ommended that reference case analyses measure health effects
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in terms of QALYs. Standardizing methods and components
within a perspective is intended to enhance consistency and com-
parability across studies.
Recommendation 2: Health Care Sector Reference Case
Results of the health care sector reference case analysis should be
summarized in the conventional form as an incremental cost-
effectiveness ratio.Netmonetarybenefit or net healthbenefitmay
alsobereported,andarangeofcost-effectiveness thresholdsshould
be considered. In addition, the health care sector perspective
should include formal health care sector (medical) costs reim-
bursedby third-partypayersorpaidout-of-pocketbypatients.Both
types of medical costs include current and future costs both re-
lated and unrelated to the condition under consideration.
Recommendation 3: Societal Reference Case
Recommendation 3A: Inclusion of an Impact Inventory | Evaluation
of the broader effects of interventions designed to improve health
is strongly recommended. The societal reference case analysis
should includemedical costs (current and future, related andunre-
lated) borne by third-party payers and paid out-of-pocket by pa-
tients, timecostsofpatients in seekingandreceivingcare, timecosts
of informal (unpaid) caregivers, transportation costs, effects on fu-
tureproductivity andconsumption, andother costs andeffectsout-
side thehealthcaresector.Tomake thisevaluationmoreexplicit and
transparent, inclusion of an “impact inventory” that lists the health
and nonhealth effects of an intervention should be considered in a
societal referencecaseanalysis (described inmoredetail belowand
in the Figure 1). Themain purpose of the impact inventory is to en-
sure thatall consequences, including thoseoutside the formalhealth
care sector, are considered regularly and comprehensively, which
has generally not been the case to date.
Recommendation 3B: Quantifying and Valuing Nonhealth Compo-
nents in the Impact Inventory |Analysts should attempt to quantify
and value nonhealth consequences in the impact inventory unless
those consequences are likely to have a negligible effect on the re-
sult of the analysis.
Figure 1. Impact Inventory Template
Sector
Type of Impact
(list category within each sector with unit of
measure if relevant)a
Formal Health Care Sector
Health
Health outcomes (effects)
Informal Health Care Sector
Included in This
Reference Case Analysis
From…Perspective?
Notes on
Sources of
EvidenceHealth Care
Sector
Societal
Longevity effects
Health-related quality-of-life effects
Other health effects (eg, adverse events
and secondary transmissions of infections)
Medical costs
Paid for by third-party payers
Health
Patient-time costs NA
Non−Health Care Sectors (with examples of possible items)
Productivity
Labor market earnings lost NA
Consumption Future consumption unrelated to health NA
Social Services Cost of social services as part of intervention NA
Education Impact of intervention on educational
achievement of population
NA
Housing Cost of intervention on home improvements
(eg, removing lead paint)
NA
Environment Production of toxic waste pollution by
intervention
NA
Other (specify) Other impacts NA
Legal or
Criminal Justice
Number of crimes related to intervention NA
Unpaid caregiver-time costs NA
Cost of crimes related to intervention NA
Cost of unpaid lost productivity due to illness NA
Cost of uncompensated household productionb NA
Transportation costs NA
Paid for by patients out-of-pocket
Future related medical costs (payers
and patients)
Future unrelated medical costs (payers
and patients)
a Categories listed are intended
as examples for analysts.
bExamples include activities such
as food preparation, cooking,
and clean up in the household;
household management; shopping;
obtaining services; and travel
related to household activity.18
NA indicates not applicable.
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Recommendation3C:SummaryandDisaggregatedMeasures| Itwould
behelpful to informdecisionmakers through thequantificationand
valuation of all health and nonhealth effects of interventions, and
to summarize those effects in a single quantitative measure, such
as an incremental cost-effectiveness ratio, netmonetarybenefit, or
net health benefit. However, there are no widely agreed on meth-
ods forquantifyingandvaluingsomeof thesebroadereffects incost-
effectiveness analyses. Analysts should present the items listed in
the impact inventory in the form of disaggregated consequences
across different sectors. It is also recommended that analysts use 1
or more summary measures, such as an incremental cost-
effectiveness ratio, netmonetarybenefit, ornethealthbenefit, that
include some or all of the items listed in the impact inventory. Ana-
lysts should clearly identifywhich items are included and how they
aremeasuredandvalued, andprovide a rationale for theirmethod-
ological decisions.
Recommendation 4: Reporting the Reference Cases
andOther Perspectives
Recommendation4A:StatingthePerspective |Analystsshouldclearly
state the perspective of every analysis reported.
Recommendation 4B: Presenting Other Perspectives |When spe-
cific decisionmakers havebeen identified, suchas aparticular pub-
lic or private payer, analysts may want to present results from that
decisionmaker’sperspective inaddition to the2 referencecaseper-
spectives. In these cases, analysts should indicatewho the primary
decision makers were whose deliberations are intended to be in-
formed by the analysis.
Recommendation 4C: Importance of Transparency and Sensitivity
Analysis | The items included in a cost-effectiveness analysis and
the manner in which they are valued involve numerous choices.
Analysts should be transparent about how they have conducted
the analyses, and convey how the results change with alternative
assumptions. Sensitivity analysis should describe the assump-
tions to which the results for different perspectives are sensitive.
Other Recommendations Regarding the Design
and Conduct of Cost-effectiveness Analyses
It is important to focuson relevant researchquestions,maintain the
focus as the study progresses, and avoid analytic pitfalls. A written
protocol at the outset of an analysis that details key aspects of the
design and conduct of the cost-effectiveness analysis is recom-
mended(eg, thestudyobjective; the intervention, comparators, and
populationsunder consideration; the timehorizon; sourcesofdata;
a list of key assumptions).
In termsofvaluinghealthoutcomes, theSecondPanel (inagree-
mentwiththeoriginalpanel) recommendsthat (1) thereferencecase
cost-effectiveness analyses shouldmeasurehealth effects in terms
ofQALYs (includingQALYs accruing to patients and to any other af-
fectedparties suchascaregivers); (2)qualityweights shouldbepref-
erence based and interval scaled; and (3) community preferences
for health states are themost appropriate sourceofpreferences for
reference case analyses. Theuseof generic preference-basedmea-
sures is recommended toenhancecomparability across studies, but
it is emphasized that the instrument used should be fit for purpose
in the sense that itsmeasurement properties are adequate tomea-
sure thedifferences and changes in health across the interventions
under consideration. Although generic preference-based mea-
sures should be used for the reference case analyses, analystsmay
also want to present estimates based on scores obtained from pa-
tients or from other sources.
In a departure from the original panel, the Second Panel ob-
serves that, in general, effects on productivity are unlikely to have
been captured by most preference-based measures, and that evi-
dence is not definitive that the effects of morbidity on leisure are
necessarily reflected intheutilityscoresorquality-of-lifeweights.19-25
Therefore, it is recommended that the productivity consequences
related to changes in health status be reflected in the numerator of
cost-effectiveness ratios for reference caseanalyses conductedun-
der the societal perspective, while recognizing the possibility that
the uncertainty about how productivity and the effects ofmorbid-
ity on leisure activities are captured in preference-basedmeasures
could leadtodoublecounting.Researchrecommendationsaremade
to develop improved quality-of-life weights that would avoid such
double counting.
In terms of estimating costs for cost-effectiveness analyses, a
keydeparture fromtheoriginalpanel is theconsiderationofcostcat-
egories from the 2 reference case perspectives. It is now recom-
mendedthatsomecomponents (eg,currentandfuturemedicalcosts
and patients’ out-of-pocket costs) should be included in both per-
spectives, while others (eg, time costs for patients and caregivers,
transportation costs, productivity benefits, consumption costs,
and other non–health-care sector costs) should be included only in
the societal reference case perspective (Table 1). The new recom-
mendations also suggest inclusion of future costs (ie, that cost-
effectiveness analyses account for related or unrelated health care
Table 1. Cost Components Included in the 2 Recommended Reference
Case Perspectives
Cost Component
Reference Case Perspective
Health Care Societal
Formal Health Care Sectora
Costs paid by third-party payers Yes Yes
Costs paid out-of-pocket by patients Yes Yes
Informal Health Care Sector
Patient-time costs No Yes
Unpaid caregiver-time costs No Yes
Transportation costs No Yes
Non–Health Care Sectors
Productivity No Yes
Consumption No Yes
Social services No Yes
Legal or criminal justice No Yes
Education No Yes
Housing No Yes
Environment No Yes
Other (eg, friction costs) No Yes
a Includes current and future costs related and unrelated to the condition under
consideration.
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costs that occur during the additional life-years produced by an in-
tervention). Theoriginal paneldiscussed this issuebutdidnot reach
consensus (noting that analysts could use their discretion) due to
the lack of a developed theoretical basis for including future costs
at the time of its report.26-34
It is important to interpret, adjust, and synthesize evidence in
a cost-effectiveness analysis, drawing on recent guidance regard-
ing systematic reviews andmeta-analyses. Among the recommen-
dations, analysts should (1) provideaqualitativedescriptionandcri-
tique of the evidence base, (2) be explicit about whether and how
bias in each study and across studies in the evidence was handled,
(3) produce bias-corrected estimates, and (4) be explicit about
whether and how estimates were adjusted for transferability.
Costs andhealth effects shouldbediscounted at the same rate
in cost-effectivenessanalyses. Furthermore, givenavailabledataon
real economic growthandcorrespondingestimatesof the real con-
sumption rate of interest and to promote comparability across
studies, 3% is the most appropriate real discount rate for cost-
effectiveness analyses. However, the panel recommends conduct-
ing sensitivity analyses that allow for a reasonable range of rates,
along with more research on the topic of using different discount
rates for costs and health effects in cost-effectiveness analyses.
Recommendations Regarding Reporting
and Interpreting Cost-effectiveness Analyses
Organization and clarity in reporting cost-effectiveness analyses35
are important and there are expanded recommendations to im-
prove and standardize reporting (Figure 2). Analysts should docu-
ment cost-effectiveness analyses in both a journal article and in a
technical appendix.
All of the elements included in the reporting checklist should be
briefly covered in the journal article, with additional detail provided
within the technical appendix. There are no specific recommenda-
tions onwhich elements are of the highest priority because thismay
depend to some extent on the specifics of the analysis. Typical ele-
ments often covered primarily in the technical appendix include
detailed reporting of intermediate outcomes and disaggregated re-
sults,uncertaintyandsecondaryanalyses,modelingassumptions,evi-
dencesynthesis,modelvalidation,and informationonsourcesofdata
regarding effectiveness, cost, and preferences.
Inclusion of a structured abstract for journal articles, incorpo-
ration of an impact inventory to aid analysts in providing a com-
plete and transparent account of the reference cases, reporting of
intermediate end points and disaggregated results, and disclosure
of potential conflicts of interest are recommended.
Structured Abstract
Although each journal may have its own requirements, it is recom-
mended that a structured abstract specifically designed for cost-
effectivenessanalysesshouldbe included inthe journalarticlewhen-
ever possible (Table 2).
Impact Inventory
As noted, the new reference case recommendations mean report-
ingof results fromboththehealthcaresectorperspectiveandtheso-
cietal perspective. Analysts should clearly delineate the results from
the 2 reference case perspectives and identify differences using the
impact inventory(Figure1).Analystsshouldconsiderthedecisioncon-
textwhendetermining ifone referencecaseperspective is tobepre-
sented in greater detail than the other. The discussion section of the
journal article should address qualitative and quantitative differ-
ences between the 2 reference case perspectives. It is important to
highlight the components of the impact inventorymost affected by
the condition or those that differ between the 2 perspectives.
For interventions that have substantial effects beyond the for-
mal health care sector, such as those that address public health pro-
gramsor children’s health, it is important tohighlightdifferencesbe-
tween the health care sector and societal perspectives. If a sector or
consequence within a sector is identified but excluded from a cost-
effectivenessanalysis, analysts shouldprovideabrief rationale in the
accompanying text or in the “Notes on Sources of Evidence” section
of the impact inventory. The impact inventory should be completed
andreported forall analyses, even those restricted to thehealthcare
sector to highlight any effects or costs not fully addressed.
For all analyses, the impact inventory should identify the sec-
tors affected and list the specific types of impacts within each sec-
tor. If the results in the societal reference case differ substantially
fromthose in thehealth care sector reference case, all identifiedef-
fects should ideally be quantified, valued if possible, and reported
in the results section. Items in categories not estimated quantita-
tively shouldbenamed in the impact inventoryandaddressed in the
discussion section, the technical appendix, orboth.Analysts should
initially consider theelementsof the impact inventory aspart of the
design exercise for an analysis and then include the completed im-
pact inventory in the journal article (or in the technical appendix if
space limitations preclude inclusion in the journal report).
Reporting of Intermediate End Points
and Disaggregated Results
Incremental cost-effectiveness ratiosprovideaconcise summaryof
the results. The panel recommends that information on intermedi-
ate outcomes and disaggregated results should also be included in
the journal articlewithmoredetail provided in the technical appen-
dix. Intermediateoutcomessuchasdiagnoses, testoutcomes,health
events, or hospitalizations provide readers with an opportunity to
assess theeffectivenessof the interventions inmore familiar terms,
and to compare the resultswith other analyses thatmayhave used
similar outcomes. The reportingof disaggregated results,which re-
fers to the attribution of total costs orQALYs to specific categories,
can help audiences understand the different magnitudes of eco-
nomic and health consequences.
Interpreting Results for DecisionMakers
Because fewdecisionmakers in theUnited States or elsewhere use
strict cost-effectiveness thresholds for decision making, conclu-
sionsaboutthecost-effectivenessofaninterventionshouldbeframed
with respect to the decision context and how the specific set of re-
sults can aid and inform decisionmaking.36 Comparisonwith 1 spe-
cific threshold should be avoided (unless appropriate for the deci-
sioncontext); analystsshould insteadhighlighthowclinicalorpolicy
recommendations might change with consideration of a range of
thresholds.37Comparingcost-effectivenessresultswiththoseofsimi-
lar interventions isalsorecommended.Thediscussionsectionof the
journal article is the appropriate place to consider these issues.
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Disclosure of Potential Conflicts of Interest
Disclosure policy for authors of cost-effectiveness analyses should
follow the standards formulatedby the International Committeeof
Medical Journal Editors.
Worked Examples
Within the full report of the Second Panel,8 2 new worked
examples (one focusing on alcohol use disorders and another on
end-of-life care) are included. These worked examples demon-
Figure 2. Reporting Checklist for Cost-effectiveness Analyses
Introduction
Element Journal Article Technical Appendix
Background of the problem
Study Design and Scope
Methods and Data
Objectives
Audience
Type of analysis
Target populations
Description of interventions and comparators (including no intervention, if applicable)
Time horizon
Other intervention descriptors (eg, care setting, model of delivery, intensity and timing of intervention)
Analytic perspectives (eg, reference case perspectives [health care sector, societal]; other perspectives such as employer or payer)
Trial-based analysis or model-based analysis. If model-based:
Identification of key outcomes
Impact Inventory
Full accounting of consequences within and outside the health care sector
Results
Results of model validation
Disclosures
Statement of any potential conflicts of interest due to funding source, collaborations, or outside interests
Discussion
Summary of reference case results
Summary of sensitivity of results to assumptions and uncertainties in the analysis
Discussion of the study results in the context of results of related cost-effective analyses
Limitations of the study
Relevance of study results to specific policy questions or decisions
Discussion of ethical implications (eg, distributive implications relating to age, disability, or other characteristics of the population)
Reference case results (discounted and undiscounted): total costs and effectiveness, incremental costs and effectiveness, incremental
cost-effectiveness ratios, measures of uncertainty 
Disaggregated results for important categories of costs, outcomes, or both
Results of sensitivity analysis
Other estimates of uncertainty
Graphical representation of cost-effectiveness results
Graphical representation of uncertainty analyses
Aggregate cost and effectiveness information
Secondary analyses
Description of event pathway or model (describe condition or disease and the health states included)
Diagram of event pathway or model (depicting the sequencing and possible transitions among the
health states included)
Description of model used (eg, decision tree, state transition, microsimulation)
Modeling assumptions
Software used
Complete information on sources of effectiveness data, cost data, and preference weights
Methods for obtaining estimates of effectiveness (including approaches used for evidence synthesis)
Methods for obtaining estimates of costs and preference weights
Critique of data quality
Statement of costing year (ie, the year to which all costs have been adjusted for the analysis; eg, 2016)
Statement of method used to adjust costs for inflation
Statement of type of currency
Source and methods for obtaining expert judgment if applicable
Statement of discount rates
Whether this analysis meets the requirements of the reference case
Analysis plan
Boundaries of the analysis; defining the scope or comprehensiveness of the study (eg, for a screening program, whether only a subset
of many possible strategies are included; for a transmissible condition, the extent to which disease transmission is captured;
for interventions with many possible delivery settings, whether only one or more settings are modeled)
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strate how to report results for both reference case perspectives,
use of the impact inventory, sample methods for displaying cost-
effectiveness analysis results, uncertainty analyses, sensitivity
analyses, and examples of intermediate outcomes and disaggre-
gated results.
Discussion
The goal of the Second Panel was to promote the continued evolu-
tion of cost-effectiveness analysis and its use to support judicious,
efficient, and fair decisions regarding the use of health care re-
sources. Comparability across cost-effectiveness analyses is highly
desirable if the technique is to help decision makers evaluate
tradeoffs. Inclusion of standardized components, and standardiza-
tion of methods within a perspective, is intended to enhance con-
sistency and comparability across studies.
Differentiatingbetween thehealth care sectorperspectiveand
the societal perspective will provide more clarity to consumers of
cost-effectiveness analyses than has been the case in recent years.
Thecommonpracticeofpresentingananalysis fromthehealth care
sector perspective and labeling it a societal perspective has cre-
ated the impression that these 2 perspectives are the same when
theyarenot. Clarity aboutperspective is further emphasizedby the
recommendations that analysts should identify any specific deci-
sion maker whose decisions are intended to be influenced by the
analysis, and conduct additional analyses from perspectives spe-
cific to that decision maker if those analyses will provide useful in-
formation.Manychallenges remain, suchasvaluationofeffectsout-
side the health care sector and coordination with other methods
already used to evaluate those effects, such as cost-benefit analy-
sis. Addressing these challenges will continue to provide opportu-
nities to advance the field of cost-effectiveness analysis.
These reporting recommendationshighlight the referencecase
perspectives and delineation of the impact inventory. A review of
existing reporting recommendations was conducted and included
adiscussionof thepossibleadoptionof theConsolidatedHealthEco-
nomic Evaluation Reporting Standards (CHEERS)38 for endorse-
ment (one of the panel members and one of the leadership group
were involvedwith theDelphi process for the CHEERS guidelines).
However, specific reporting requirements for thereferencecasepre-
cluded the direct adoption of CHEERS or other available reporting
guidelines.TherecommendationsfromtheSecondPanelsharemany
elements with the CHEERS recommendations, which, in turn, re-
flect elements of the original panel’s recommendations.
Substantial attentionhasbeen focusedonethical issues in cost-
effectiveness analyses, reflecting the importance of the topic and
developments in the field. Considerationof theopportunity cost of
an intervention isethically justified.Without suchconsideration,de-
cision makers would not know if there were better uses of the re-
sources at hand. These recommendations also reaffirm the prin-
ciples that cost-effectiveness analysis is not by itself a sufficient
decision-making standard and that it does not capture all relevant
concerns.Maximizing the total quantityofhealthbenefitswill rarely
be theonlyconcern fordecisionmakers.Whoreceives thebenefits—
the distributive concern—also matters. Such decisions involve
tradeoffs between effects and costs for some patients vs different
effects and costs for other patients.
The use of QALYs in cost-effectiveness analysis raises possible
ethical and other concerns. A key advantage of QALYs is that they
reflect effects on bothmorbidity andmortality and provide a basis
for broad comparisons of the health effects of various interven-
tions and policies. But there are a number of disadvantages associ-
atedwith theQALY framework. For instance, QALYsmay not accu-
rately reflect theburdenofshort-livedbut intenseexperiences.Thus
the benefits of interventions that reduce the incidence of such
Table 2. Elements Recommended for Inclusion in a Structured Abstract for Cost-effectiveness Analyses
Element Suggested Content
Objective Succinctly state the research question specific to the analysis.
Interventions List all interventions included in the analysis, including the comparators. Identify the time frame of the interventions.
Target population Identify the age ranges, clinical characteristics, and other characteristics for all subgroups evaluated in the analysis.
Perspectives Identify whether the analysis uses the reference case perspective and any alternative perspective presented.
Time horizon Specify the time horizon for the analysis. This may differ from the time frames of the interventions and the comparators.
Discount rate Specify the discount rate used in the analysis.
Costing year Specify the costing year used in the analysis.
Study design Describe whether this is a trial-based or model-based analysis. If it is a model-based analysis, briefly describe the model type
(eg, decision tree, state transition, microsimulation, discrete event) and the size and characteristics of the simulated population.
Indicate whether the analysis meets the reference case requirements.
Data sources Describe the types of data used to derive inputs for the analysis (eg, primary data, secondary data from the published literature,
administrative data, unpublished trial data).
Outcome measures List primary and secondary outcome measures (eg, incremental cost-effectiveness ratio in dollars per quality-adjusted life-year,
dollars per life-year, or dollars per clinical end point; total costs; total quality-adjusted life-years for a specified cohort;
or population-level outcomes).
Results of analysis
Base case Briefly describe the results for the primary outcome measures, as well as the notable results for intermediate outcomes
and disaggregated results (eg, deaths averted, hospitalizations averted, specific subcategories of costs).
Identify any substantial changes in non–health-care–sector consequences.
Uncertainty Briefly describe whether the results are robust to changes explored in the uncertainty analyses.
Limitations Describe important limitations of the analysis such as controversial assumptions.
Conclusions Summarize the key clinical or policy conclusions.
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experiencesmaybeundervalued. Furthermore, in the standard ap-
proach to estimating QALYs, the QALYs gained due to an interven-
tion that generatesmarginal gains formanypeoplemaybeapproxi-
mately equal to theQALYsgainedbyan intervention that generates
substantial gains for a small number of people, yet society may fa-
vor the latter. Similarly, some have argued that treating those who
initiallyexperiencehighly impairedhealth ismorevaluablethantreat-
ing thosewith good baseline health. These and other issues are ex-
plored further in the forthcoming book.
Numerouspolicyquestionsrelatedtotheuseofcost-effectiveness
analysis were considered. Even though cost-effectiveness analy-
ses have been published widely in the United States, and have
been used to inform policy in selected areas, the application
of cost-effectiveness analysis has also encountered resistance. For
example, the Medicare program is barred from considering cost-
effectiveness analysis in its decisions about whether to pay
for new therapies and diagnostics. Notably, the Patient Protection
and Affordable Care Act39 prohibited the Patient-Centered Out-
comes Research Institute from developing or using a dollars-per-
QALY metric as a threshold to establish what type of health care
is cost-effective or recommended, and stated that the “Secretary
shall not utilize such an adjusted life year (or such a similar mea-
sure) as a threshold to determine coverage, reimbursement, or in-
centive programs….”
Reasons for the resistance to cost-effectiveness analysis are
likely multifaceted and complex but suggest an inclination on the
part of many individuals in the United States to minimize the un-
derlying problem of resource scarcity and the consequent need to
explicitly rationcare.Experienceshowsthatwhenpolicymakershave
incorporated cost-effectiveness analysis intodecision-makingpro-
cesses, they have not applied it as the sole decision criterion.40,41
In practice,multiple factors are brought to bear on resource alloca-
tiondecisions. Cost-effectiveness is only 1 element amongmany, in-
cludingpatient’sexpectations; legal, ethical, equity, cultural, andpo-
litical concerns; andpragmatic issuesof logisticsand feasibility.Most
health organizations involved in resource allocation decisions give
the greatest weight and deepest consideration to the clinical evi-
dence. Cost-effectiveness analysis canplay an important role, how-
ever, particularlywhen it is recognized that costs are effectively op-
portunities for health improvement that other patients forgo.
Updating the original panel’s work provided an opportunity to
reflect on the evolution of cost-effectiveness analysis and to de-
velop guidance for the next generation of practitioners and con-
sumers. Similar toanyconsensuspanel, these recommendations re-
flect aneffortbyaselectedgroupof individuals toachieveasensible
andworkable arrangement.Other groupsmayhavedevelopeddif-
ferent recommendations.
Some key areas for future research include (1) the use of multi-
criteria decision analysis and group decision making; (2) the use
of cost-effectiveness analysis in value-based pricing; (3) estimation
of cost-effectiveness thresholds; (4) the link between cost-
effectiveness analysis and incentives for innovation; (5) the role of
cost-effectiveness analysiswithin health plans or guideline develop-
ment; and (6) the effect of the 2 recommended reference case per-
spectivesonthecost-effectiveanalysisanditsfindings.Thefieldwould
alsobenefit fromfurther researchonQALYs, including topics suchas
whether and to what extent respondents consider productivity ef-
fects in their evaluationsofhealthstates, the relationshipofcommu-
nitypreferencestopatientpreferences fordifferenthealthstates, the
elicitationofpreferencescores forpathstates, thesequenceofstates
that patients experience, and the methods for measuring health-
relatedquality-of-lifeeffectsonfamilymembersof ill individuals (fam-
ily spillover effects).
Conclusions
The Second Panel reviewed the current status of the field of cost-
effectiveness analysis and developed a new set of recommenda-
tions.Major changes include the recommendation toperformanaly-
ses from 2 reference case perspectives and to provide an impact
inventory to clarify included consequences.
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